The Implementation of an Advanced Treatment Planning Algorithm in the Treatment of Lung Cancer with Conventional Radiotherapy

Effects of electron density force to 1.0 and fill to 1.0 on VMAT treatment plans for lung SBRT

PURPOSE

The aim of this study is to determine the effect of forcing and filling the electron density (ED) to 1.0 of the planning target volume (PTV) overdose distribution in lung SBRT treatment leading to shortening patient treatment time and increasing patient comfort by reducing MU/fraction due to ED manipulation effect.

METHODS

In this study, 36 lung SBRT plans of 12 suitable patients who prescribed a total dose of 50 Gy in five fractions were generated with Monaco v.5.10 TPS using the Monte Carlo (MC) algorithm and volumetric modulated arc therapy (VMAT) technique by PTV ED values forcing as well as filling to 1.0 and comparatively assessed. The first group of plans was created by using the patient's original ED, second and third groups of plans were reoptimized by forcing and filling the ED of PTV to 1.0, respectively, therefore acquiring a new dose distribution which lead to comparatively assessment the effects of changes in ED on PTV and OAR doses.

RESULTS

Assessment of treatment plans revealed that mean MU/fx numbers were decreased by 76% and 75.25% between Groups 1 and 2, Groups 1 and 3, respectively. The number of segments was also reduced in Group 1 by up to 15% compared with Groups 2 and 3. Maximum HI and CI differences for PTV between Groups 1 and 2 were less than 1% and Groups 1 and 3 were 1.5% which indicates all 3 group plans were comparable in terms of dose distribution within PTV.

CONCLUSIONS

Forcing and filling the ED of PTV to 1.0 strategy has provided reduced a number of segments and MU/fx without a significant change in PTV mean and maximum doses, thereby decreasing treatment time and patient discomfort during treatment. This process should be considered in line of a potential number of patients as well as prescribed dose and MU/fx numbers.

The dosimetric effect of electron density overrides in 3DCRT Lung SBRT for a range of lung tumor dimensions

The combined effects of lung tumor motion and limitations of treatment planning system dose calculations in lung regions increases uncertainty in dose delivered to the tumor and surrounding normal tissues in lung stereotactic body radiotherapy (SBRT). This study investigated the effect on plan quality and accuracy when overriding treatment volume electron density values. The QUASAR phantom with modified cork cylindrical inserts, each containing a simulated spherical tumor of 15‐mm, 22‐mm, or 30‐mm diameter, was used to simulate lung tumor motion. Using Monaco 5.1 treatment planning software, two standard plans (50% central phase (50%) and average intensity projection (AIP)) were compared to eight electron density overridden plans that focused on different target volumes (internal target volume (ITV), planning target volume (PTV), and a hybrid plan (HPTV)). The target volumes were set to a variety of electron densities between lung and water equivalence. Minimal differences were seen in the 30‐mm tumor in terms of target coverage, plan conformity, and improved dosimetric accuracy. For the smaller tumors, a PTV override showed improved target coverage as well as better plan conformity compared to the baseline plans. The ITV plans showed the highest gamma pass rate agreement between treatment planning system (TPS) and measured dose (P < 0.040). However, the low electron density PTV and HPTV plans also showed improved gamma pass rates (P < 0.035, P < 0.011). Low‐density PTV overrides improved the plan quality and accuracy for tumor diameters less than 22 mm only. Although an ITV override generated the most significant increase in accuracy, the low‐density PTV plans had the additional benefit of plan quality improvement. Although this study and others agreed that density overrides improve the treatment of SBRT, the optimal density override and the conditions under which it should be applied were found to be department specific, due to variations in commissioning and calculation methods.

Oesophageal Chemoradiotherapy in the UK--current practice and future directions

The SCOPE 1 trial closed to recruitment in early 2012 and has demonstrably improved the quality of UK radiotherapy. It has also shown that there is an enthusiastic upper gastrointestinal clinical oncology community that can successfully complete trials and deliver high-quality radiotherapy. Following on from SCOPE 1, this paper, authored by a consensus of leading UK upper gastrointestinal radiotherapy specialists, attempts to define current best practice and the questions to be answered by future clinical studies. The two main roles for chemoradiotherapy (CRT) in the management of potentially curable oesophageal cancer are definitive (dCRT) and neoadjuvant (naCRT). The rates of local failure after dCRT are consistently high, showing the need to evaluate more effective treatments, both in terms of optimal local and systemic therapeutic components. This will be the primary objective of the next planned UK dCRT trial and here we discuss the role of dose escalation and systemic therapeutic options that will form the basis of that trial. The publication of the Dutch 'CROSS' trial of naCRT has shown that this pre-operative approach can both be given safely and offer a significant survival benefit over surgery alone. This has led to the development of the UK NeoSCOPE trial, due to open in 2013. There will be a translational substudy to this trial and currently available data on the role of biomarkers in predicting response to therapy are discussed. Postoperative reporting of the pathology specimen is discussed, with recommendations for the NeoSCOPE trial. Both of these CRT approaches may benefit from recent developments, such as positron emission tomography/computed tomography and four-dimensional computed tomography for target volume delineation, planning techniques such as intensity-modulated radiotherapy and 'type b' algorithms and new treatment verification methods, such as cone-beam computed tomography. These are discussed here and recommendations made for their use.

Dosimetric impact of a frame-based strategy in stereotactic radiotherapy of lung tumors

INTRODUCTION

Technological innovations have taken stereotactic body radiotherapy (SBRT) from frame-based strategies to image-guided strategies. In this study, cone beam computed tomography (CBCT) images acquired prior to SBRT of patients with lung tumors was used to study the dosimetric impact of a pure frame-based strategy.

MATERIAL AND METHODS

Thirty patients with inoperable lung tumors were retrospectively analyzed. All patients had received CBCT-guided SBRT with 3 fractions of 15 Gy to the planning target volume (PTV) margin including immobilization in a stereotactic body frame (SBF). Using the set-up corrections from the co-registration of the CBCT with the planning CT, all individual dose plans were recalculated with an isocenter position equal to the initial set-up position. Dose Volume Histogram (DVH) parameters of the recalculated dose plans were then analyzed.

RESULTS

The simulated plans showed that 88% of all fractions resulted in minimum 14.5 Gy to the internal target volume (ITV). For the simulated summed treatment (3 fractions per patient), 83% of the patients would minimum receive the prescription dose (45 Gy) to 100% of the ITV and all except one would receive the prescription dose to more than 90% of the ITV.

CONCLUSIONS

SBRT including SBF, but without image guidance, results in appropriate dose coverage in most cases, using the current margins. With image guidance, margins for SBRT of lung tumors could possibly be reduced.